ICV introduces CEOs of the Private Sector to Family Offices, Institutional Investors, Potential Partners and Government Officials in Asia.


Our comprehensive and customized delegation visits provide insights into operating throughout Asia and U.S. – Asia relations, as well as the opportunity to explore potential investment and cross-border partnering opportunities.

Africa, Europe, the Middle East and United States


Asia Placeholder





ICV Delegation Visit Greater China 2017, Week of November 13

In China, meetings are less transactional than in other markets and sustained follow-ups and visits are the key to establishing long-term relationships. Because of this, ICV will customize visits based upon company objectives and advise clients on their China strategy. High-level, one-on-one meetings are arranged that have direct follow-up implications and facilitate a variety of different partnering mechanisms for co-development and/or investment. Beyond the meeting, ICV provides follow-up and ongoing communication regarding company releases to help multiple stakeholders stay informed.

Within healthcare, the Chinese market is developing rapidly, with true innovation starting to happen, and an aggressive move towards cross-border collaboration, both for investments and licensing. ICV introduces biotech and medical device companies to government officials, large pharmaceutical companies, and Family Offices and Fund Investors located throughout Greater China.

ICV Delegation Visit Japan 2017, Week of October 9

Japan is one of the world’s most developed and sophisticated healthcare markets, especially in the biopharmaceutical and medical technology space. Behind the U.S., Japan is the second world’s second-largest pharmaceutical market. Japan not only has a complex and rewarding reimbursement scheme for marketed products, but a vibrant R&D landscape with particularly innovative incentives. In areas such as Regenerative Medicine, for instance, Japan is the global leader, having implemented a unique regulatory mechanism in 2014 for the expedited approval of Regenerative Medicines.

On a macro level, the country’s rapidly aging population, with the 65-and-older demographic on track to increase from 25% to 40% of the population, presents huge challenges for government and the economy and creates huge opportunities for innovation and international expansion. Because of this, Japan is increasingly opening up to foreign markets and to international companies operating within the country.


Delegation Visit Taiwan, June 26 – July 2, 2017

Taiwan’s boom in biotechnology means licensing, partnering and investment agreements are at an all-time high. 

ICV will host Delegation Visit Taiwan, a week-long roadshow with one-on-one meetings with investors and access to BioTaiwan 2017.

Unique characteristics make the biotech industry in Taiwan an appealing prospect to the global life science community looking for partnership, investment or licensing opportunities.

  • Vibrant VC industry and capital markets
  • Strong business and cultural ties to the Greater China market
  • World-class clinical trial capability
  • Transparent legal and business environment, with strong IP protection
  • Well established private-public partnerships with deep innovation pipelines
  • Highly-educated, motivated and cost-effective workforce
  • Executives with overseas training, global view and Big Pharma experience
  • Strong government support, subsidies and tax breaks


Delegation Visit China and Singapore, Spring 2017

This spring, ICV introduced one of its innovative biopharmaceuticals clients to potential partners and investors in China and Singapore.

With nearly three dozen one-on-one meetings scheduled in total, adding up to tens of billions in combined fund AUM, interest in Asia has proved strong for U.S. biopharmaceuticals. These meetings have had direct follow-up implications, with several investors now conducting a deeper dive.

Chinese partners and investors are continuing to look for mid to late-stage clinical assets combatting a variety of severe diseases in China.

In Singapore, interest is in early-stage opportunities, with more of a focus on platform technologies, medical devices and hospital-oriented services.



Delegation Visit Greater China: Beijing, Shanghai and Hong Kong, Winter 2017

Morning / Afternoon Arrival
Black car service to hotel arranged by ICV.
Beijing International Airport
Evening Hotel Check-in & Welcome Park Hyatt Beijing
19:00 Pre-trip informal dinner & drinks to get acquainted with delegation participants Duck de Chine



Monday, 6 February 2017 – Beijing

8:00 to 11:30 Breakfast & Morning Introductory Seminar
Briefings by senior industry experts and U.S. Embassy officials, and key opinion leaders to provide background on U.S. – China relations and the status of the biotechnology industry and policy in China
Park Hyatt Beijing
12:00 to 14:00 Lunch Hosted by Chinese Central Government
Investment Promotion Agency – China Center for the Promotion of International Trade (CCPIT)
Diaoyutai State Guest House
14:30 to 16:00 Roundtable discussion hosted by the Beijing-based Biotechnology Industry and Investor Community Park Hyatt Beijing
16:00 to 19:00 Beijing Community Meetings
Dinner hosted by former American Government and Chinese Ministry of Commerce Officials to discuss current status of U.S.-China relationship and networking opportunities with Chinese investor community.
Park Hyatt Beijing
19:00 Depart for Shanghai via Flight #845 Beijing Capital Airport (PEK)



Tuesday, 7 February 2017 – Shanghai

5:00 to 8:30 Breakfast Pudong Shangri-La Hotel – Shanghai, China
10:00 to 12:00 Visit Shanghai Zhangjiang Biotechnology Park
Visit leading biotechnology companies and funds in China’s “silicon valley” to discuss investment and partnering opportunities.
Shanghai Zhangjiang Biotechnology Park
13:00 to 18:00 1:1 Investor Meetings Pudong Shangri-La Hotel – Shanghai, China
18:00 to 19:00 Networking Reception Pudong Shangri-La Hotel – Shanghai, China
20:00 to 22:00 Private Dinner w/ Shanghai-based Biotechnology leaders, Investors, & Shanghai Zhangjiang Biotechnology Park Leadership
Optional: Walk to post-dinner cocktails at M on the Bund overlooking the river.
Lost Heaven Yunnan Restaurant



Wednesday, 8 February 2017 – Shanghai

9:00 to 12:00 Participation in Opening Plenary, Keynote speech at China Healthcare Investor Conference (CHIC) Pudong Shangri-La Hotel – Shanghai, China
12:00 to 14:00 Private Delegation Lunch with key China Healthcare Investors Pudong Shangri-La Hotel – Shanghai, China
14:00 to 17:00 Continued Participation in China Healthcare Investor Conference (CHIC) Pudong Shangri-La Hotel – Shanghai, China
18:00 to 20:00 Dinner hosted by Shanghai Municipal Government Leadership Shanghai Dong Jiao State Guest



Thursday, 9 February 2017 – Shanghai & Hong Kong

9:00 Hotel Meetings with Shanghai Institutional & Private Wealth Investor Community Pudong Shangri-La Hotel – Shanghai, China
12:00 to 13:00 Check-out & Boxed Lunch Pudong Shangri-La Hotel – Shanghai, China
13:55 Depart for Hong Kong via Shanghai Airlines Flight #845 Shanghai Hongqiao Airport
16:15 Arrive in Hong Kong Hong Kong International Airport
17:30 Check-in to Hotel Grand Hyatt Hong Kong
19:00 to 21:00 Cocktail Reception with Hong Kong-based Institutional & Private Investor Community Followed by Dinner SEVVA
Prince’s Building 25th Floor
Central, HK



Friday, 10 February 2017 – Hong Kong

9:00 to 12:00 Visits to Hong Kong Institutional & Private Investor Offices Hong Kong
12:00 to 13:30 Hedge Fund Managers Group Lunch
A lunch discussion and meet-and-greet at Hong Kong’s most stylish dim sum establishment.
Fook Lam Moon
35-45 Johnston Road, Wanchai, HK
14:00 to 16:00 Visit to Hong Kong University of Science and Technology HKUST
Clear Water Bay, HK
17:00 to 19:00 Cocktail Reception with Hong Kong Consulate & U.S. Business Community in Hong Kong Foreign Correspondents Club
Hong Kong
20:00 to 21:00 Delegation Closing Dinner & Summary of Events – Next Steps Discussion Grand Hyatt Hotel, Hong Kong



Saturday, 11 February 2017 – Hong Kong

Morning / Afternoon Departure via independent flights Hong Kong International Airport


* Flights, in-market transportation, meals, translators, and hotel costs are covered by delegates.
* A concurrent tourist itinerary will be set up for significant others.